Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial
- 1 May 2019
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (5) , 1599-1609.e1
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Novartis
- Novartis
- Novartis
- Novartis
This publication has 38 references indexed in Scilit:
- Cholinergic urticaria patients of different age groups have distinct featuresClinical & Experimental Allergy, 2017
- Cholinergic urticaria: epidemiology, physiopathology, new categorization, and managementClinical Autonomic Research, 2017
- Sweat allergy: Extrinsic or intrinsic?Journal of Dermatological Science, 2017
- New Etiology of Cholinergic Urticaria2016
- Elevated Serum IgE against MGL_1304 in Patients with Atopic Dermatitis and Cholinergic UrticariaAllergology International, 2014
- Sweat antigen induces histamine release from basophils of patients with cholinergic urticaria associated with atopic diathesisBritish Journal of Dermatology, 2009
- Cholinergic urticaria associated with acquired generalized hypohidrosis: report of a case and review of the literatureBritish Journal of Dermatology, 2000
- The extent and nature of disability in different urticarial conditionsBritish Journal of Dermatology, 1999
- Demonstration of sweat allergy in cholinergic urticariaJournal of Dermatological Science, 1994
- Cholinergic Urticaria, Passive Transfer Experiments from Human to MonkeyDermatology, 1988